Scarica l'app Stockscreener
9.60
2.24%
0.21
Precedente Chiudi:
$9.39
Aprire:
$9.12
Volume 24 ore:
39,048
Relative Volume:
1.18
Capitalizzazione di mercato:
$90.18M
Reddito:
-
Utile/perdita netta:
$-129.41M
Rapporto P/E:
-0.3985
EPS:
-24.0922
Flusso di cassa netto:
$-51.97M
1 W Prestazione:
+8.23%
1M Prestazione:
+13.88%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.10
$9.6985
Intervallo di 1 settimana:
$8.03
$9.6985
Portata 52W:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Nome
Leonabio Inc
Settore
Industria
Telefono
(425) 620-8501
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
9.60 | 90.18M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-09-19 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-04 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-09-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Iniziato | Rodman & Renshaw | Buy |
| 2022-10-17 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Downgrade | Jefferies | Buy → Hold |
| 2022-06-23 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Iniziato | BTIG Research | Buy |
| 2022-04-21 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Goldman | Neutral |
| 2020-10-13 | Iniziato | Goldman | Buy |
| 2020-10-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-13 | Iniziato | Jefferies | Buy |
| 2020-10-13 | Iniziato | Stifel | Buy |
Mostra tutto
Leonabio Inc Borsa (LONA) Ultime notizie
Form 4 LeonaBio Inc For: 10 July By Investing.com - Investing.com Nigeria
LeonaBio (LONA) awards 28,000 stock options tied to Perceptive Advisors board role - Stock Titan
Form 4 LeonaBio Inc For: 9 July By Investing.com - Investing.com Nigeria
LeonaBio (LONA) director entities receive 28,000 stock options grant - Stock Titan
LeonaBio (LONA) Gains 5.85% as Biotech Stock Approaches Key ResistanceIPO Entry Watch - dars.gov.et
LONA Q1 2026 Earnings: EPS Surprise of 32% Powers 5.85% Share RallyEPS Estimate Trend - dars.gov.et
LeonaBio Inc. (LONA) Declines 1.6% Amid Mixed Technical SignalsLow Vol ETF - dars.gov.et
LeonaBio, Inc.(NasdaqCM: LONA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
LeonaBio, Inc.(NasdaqCM: LONA) added to Russell 3000E Growth Benchmark - marketscreener.com
LeonaBio, Inc.(NasdaqCM: LONA) added to Russell Microcap Index - marketscreener.com
LeonaBio, Inc.(NasdaqCM: LONA) added to Russell 3000E Index - marketscreener.com
LONALeonaBio Inc Dividends - Finviz
LONA SEC FilingsLeonaBio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enterprise value to EBIT forward of LeonaBio, Inc. – NASDAQ:LONA - TradingView
Price to sales forward of LeonaBio, Inc. – NASDAQ:LONA - TradingView
Number of shareholders of LeonaBio, Inc. – NASDAQ:LONA - TradingView
LeonaBio, Inc. Actuals & Estimates (NASDAQ:LONA) - TradingView
LONA Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 LeonaBio Inc For: 24 June By Investing.com - Investing.com South Africa
LeonaBio (LONA) director Fred Callori granted 2,333 stock options - Stock Titan
LeonaBio (LONA) director receives grant of 28,000 stock options at $8.35 - Stock Titan
[Form 4] LeonaBio, Inc. Insider Trading Activity - Stock Titan
LeonaBio (LONA) director receives 2,333 stock options at $8.35 strike - Stock Titan
LeonaBio (LONA) director receives 28,000 stock options at $8.35 exercise price - Stock Titan
LeonaBio (LONA) director awarded 28,000 stock options at $8.35 strike - Stock Titan
LeonaBio (LONA) director receives stock option grant for 28,000 shares - Stock Titan
LeonaBio (LONA) grants 28,000 stock options to director Barbara Kosacz - Stock Titan
Grant Pickering of LeonaBio (LONA) awarded 28,000 stock options at $8.35 - Stock Titan
LeonaBio Inc. (LONA) Edges Higher as Biotech Sector Shows Renewed InterestChange of Character - dars.gov.et
LeonaBio Shareholders Approve Directors, Auditor and Compensation - TipRanks
LeonaBio (NASDAQ: LONA) shareholders approve directors, EY auditor and executive pay cadence - Stock Titan
LeonaBio Ord Shs (LONA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LeonaBio Ord Shs (LONA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LeonaBio Ord Shs (LONA) Institutional Confidence - TradingKey
LONA Q1 2026 Earnings: EPS Surprises Above Estimates Amid Pre-Revenue PhaseGuidance Accuracy Score - newsline.com
LONA Q1 2026 Earnings: Narrowed Loss Exceeds Expectations as Cost Discipline ContinuesEarnings Trend Analysis - newsline.com
LeonaBio (LONA) Holds Steady Near Support as Sector Sentiment WeighsLow Beta Factor - newsline.com
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 - Investing.com UK
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 By Investing.com - Investing.com South Africa
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit - The Manila Times
Experimental ALS pill brelgometon targets Phase 2 trial in 2026 - Stock Titan
LONA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Pipeline Despite Market HeadwindsMargin Improvement Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Surprise EPS Beat Signals Progress Despite Revenue GapEstimate Uncertainty - The Legal Advocate
LeonaBio Gets $20 Price Target Ahead of June Pipeline Test - Bez Kabli
LeonaBio Inc. (LONA) Rises 1.45% as Shares Approach Key Resistance at $10.3Stock News - The Legal Advocate
LONA Initiated Coverage by Piper Sandler -- Rating Set to Overwe - GuruFocus
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June - GlobeNewswire
Piper Sandler initiates LeonaBio stock with overweight rating - Investing.com
Piper Sandler initiates LeonaBio stock with overweight rating By Investing.com - Investing.com Canada
LeonaBio Inc. (LONA) Q1 2026 Earnings: EPS Surprise Provides Bright Spot Amid Revenue Absence and Stock DeclineCash Flow Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionOperating Income Trends - The Legal Advocate
Leonabio Inc Azioni (LONA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):